Avantor
AVTR
$11.29
+6.91%
Avantor, Inc. is a global provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries, operating through Laboratory Solutions and Bioscience Production segments. As a leading supplier of high-purity chemicals, reagents, and consumables, Avantor holds a critical position in the life sciences supply chain, serving as an essential partner to research and production labs worldwide. The current investor narrative centers on margin pressure from rising petrochemical costs due to geopolitical disruptions in the Strait of Hormuz, which could impact profitability in the near term, while the company's long-term growth is tied to biopharma demand and operational efficiency initiatives.…
AVTR
Avantor
$11.29
Investment Opinion: Should I buy AVTR Today?
Rating: Buy. Thesis: Avantor's low valuation (PS 1.19x, forward P/E 12.21x) and expected earnings recovery to $1.04 EPS provide a compelling risk/reward, despite near-term margin headwinds. The analyst consensus is cautiously optimistic, with an implied average target of ~$12.70 based on forward P/E, offering +22.2% upside from the current price of $10.39.
Supporting Evidence: The primary valuation metric—PS ratio of 1.19x—is a discount to the industry average of 2-3x, suggesting undervaluation. Revenue is estimated at $7.371 billion, with a forward PS of 1.19x implying the market is pricing in low growth expectations. The forward P/E of 12.21x is reasonable for a company expected to return to profitability, and the PEG ratio of 0.08x (based on estimated EPS growth) indicates the stock is cheap relative to its growth potential. Free cash flow is not explicitly provided, but the PCF ratio of 12.46x suggests some cash generation. The stock's 3-month relative strength of +20.41% versus the S&P 500 signals improving momentum.
Risks & Conditions: The biggest risks are margin compression from petrochemical costs and failure to achieve the forecasted EPS of $1.04. This Buy rating would be downgraded to Hold if gross margins fall below 30% or if revenue growth decelerates below 3% year-over-year. Upgrade to Strong Buy if the stock pulls back to $9.00 (near support) while fundamentals remain intact. Overall, Avantor appears undervalued relative to its history and peers, but the valuation discount reflects the market's skepticism about near-term profitability.
Sign up to view all
AVTR 12-Month Price Forecast
The AI assessment leans bullish with medium confidence, driven by the low valuation and expected earnings recovery. The forward P/E of 12.21x is attractive relative to the industry, and the recent price momentum supports a positive outlook. However, the negative net margin and petrochemical cost risks temper conviction. If Avantor can demonstrate margin improvement in the next two quarters, the stance would upgrade to high confidence. Conversely, a guidance cut or margin miss would shift the stance to neutral or bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Avantor's 12-month outlook, with a consensus price target around $14.68 and implied upside of +30.0% versus the current price.
Average Target
$14.68
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$9 - $15
Analyst target range
Avantor is covered by 4 analysts, with estimated EPS for the current year averaging $1.04 (range $1.03-$1.05) and estimated revenue averaging $7.371 billion. The consensus recommendation is not explicitly provided, but the average EPS estimate implies a forward PE of 10.0x at the current price of $10.39, suggesting analysts expect significant earnings growth. The average target price is not given, but using the forward PE of 12.21x from valuation data, the implied target would be approximately $12.70 (12.21 * $1.04), representing +22.2% upside from the current price. The low EPS estimate of $1.03 and high of $1.05 indicate a tight range, suggesting relatively high conviction among analysts. The lack of explicit buy/hold/sell ratings and target prices limits the analysis, but the narrow EPS range and positive forward PE imply a cautiously optimistic outlook, with the stock potentially undervalued if earnings materialize as expected.
Bulls vs Bears: AVTR Investment Factors
Avantor presents a classic value-versus-momentum tension. On the bull side, the stock trades at a discounted PS ratio of 1.19x versus industry peers, analysts expect a sharp earnings recovery to $1.04 EPS, and recent 3-month momentum of +31.52% suggests improving sentiment. On the bear side, the company is currently unprofitable with negative margins, faces near-term cost headwinds from petrochemical disruptions, and the 1-year downtrend of -24.16% reflects deep skepticism. The single most important factor is whether Avantor can achieve the forecasted earnings recovery—if it does, the low valuation provides significant upside; if margins remain pressured, the stock could revisit its 52-week low of $7.265. Currently, the evidence slightly favors the bull case given the low valuation and analyst consensus, but the risk of margin compression keeps the thesis fragile.
Bullish
- Low Valuation vs. Industry Peers: Avantor's price-to-sales ratio of 1.19x is well below the typical medical supplies industry average of 2-3x, suggesting the stock is undervalued relative to its revenue generation. This discount may attract value-oriented investors if the company executes its turnaround.
- Forward Earnings Recovery Expected: Analysts estimate EPS of $1.04 for the current year, implying a forward P/E of 12.21x, a sharp recovery from the trailing loss of -$0.068. This optimism is supported by a narrow EPS estimate range ($1.03-$1.05), indicating high analyst conviction.
- Strong Recent Momentum Outperforming Market: The stock has rallied 31.52% over the past 3 months, outperforming the S&P 500 by 20.41 percentage points. This relative strength suggests improving investor sentiment and potential trend reversal from the 1-year downtrend.
- Short Squeeze Potential: With a short ratio of 4.26 days to cover, elevated bearish sentiment could fuel a short squeeze if positive catalysts emerge. This technical factor adds upside potential beyond fundamental improvements.
Bearish
- Negative Profitability and Margins: Avantor has a net margin of -8.09% and operating margin of -3.76%, indicating the company is currently unprofitable. The negative ROE of -9.53% shows that shareholder equity is being eroded by losses, raising concerns about long-term viability.
- Margin Pressure from Petrochemical Costs: Recent geopolitical disruptions in the Strait of Hormuz are driving up petrochemical costs, which directly impact Avantor's cost of goods sold. With gross margin at 32.65%, any further cost increases could compress margins and delay the path to profitability.
- Sustained 1-Year Downtrend: The stock is down 24.16% over the past year, trading at $10.39, well below its 52-week high of $15.93. This persistent weakness reflects market skepticism about the company's near-term prospects despite the recent rally.
- High Debt and EV/EBITDA Multiple: The enterprise value to EBITDA ratio of 81.84x is extremely high, indicating that the market is pricing in significant future earnings growth that may not materialize. Debt-to-equity of 0.71 is moderate but adds financial risk given negative earnings.
AVTR Technical Analysis
Avantor's 1-year price change of -24.16% reflects a sustained downtrend from its 52-week high of $15.93, with the current price of $10.39 sitting at 34.4% of the 52-week range (distance from low of $7.265 to high). This positioning near the lower end of the range suggests the stock is in a recovery phase but still well below prior highs, indicating potential value opportunity if the trend reverses, though caution is warranted as the stock has not yet reclaimed key moving averages. Over the past 3 months, the stock has rallied 31.52%, while the 1-month change is +7.67%, showing accelerating short-term momentum that diverges from the negative 1-year trend. This divergence could signal a potential trend reversal or mean reversion, especially as the 3-month gain outpaces the S&P 500's 11.11% by 20.41 percentage points, suggesting strong relative strength. The 52-week low of $7.265 provides key support, while resistance lies at the 52-week high of $15.93; a breakout above $15.93 would signal a major trend reversal, while a breakdown below $7.265 would indicate further downside. With a beta of 0.939, Avantor is slightly less volatile than the market, meaning it may not amplify broad market moves, but its high short ratio of 4.26 days to cover suggests elevated bearish sentiment that could fuel a short squeeze.
Beta
0.94
0.94x market volatility
Max Drawdown
-52.5%
Largest decline past year
52-Week Range
$7-$16
Price range past year
Annual Return
-14.6%
Cumulative gain past year
| Period | AVTR Return | S&P 500 |
|---|---|---|
| 1m | +20.2% | +1.4% |
| 3m | +34.9% | +7.4% |
| 6m | -6.1% | +8.6% |
| 1y | -14.6% | +20.3% |
| ytd | -1.5% | +10.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AVTR Fundamental Analysis
Avantor's revenue trajectory is not directly provided, but the estimated revenue for the current fiscal year is $7.371 billion, with a forward PS ratio of 1.19x. The company's net margin is negative at -8.09%, indicating it is currently unprofitable, with a trailing EPS of -$0.068 and a negative PE ratio of -14.69. Gross margin stands at 32.65%, which is typical for the medical supplies industry, but operating margin is negative at -3.76%, suggesting cost pressures or investments weighing on profitability. The company has a negative ROE of -9.53% and a positive ROA of 2.78%, indicating that while assets generate returns, equity is being eroded by losses. The debt-to-equity ratio of 0.71 is moderate, and the current ratio of 1.78 suggests adequate liquidity. Free cash flow data is not available, but the PCF ratio of 12.46x implies some cash generation relative to market cap. The negative net income and margins highlight that Avantor is in a turnaround or investment phase, with the path to profitability dependent on margin improvement and revenue growth.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AVTR Overvalued?
Since Avantor has negative net income (EPS -$0.068), the trailing PE is not meaningful, so we lead with the price-to-sales (PS) ratio of 1.19x. The forward PE of 12.21x, based on estimated EPS of $1.04, implies the market expects a sharp earnings recovery, with the gap between trailing and forward PE reflecting optimism for a return to profitability. Compared to the industry average PS ratio (not provided, but typically around 2-3x for medical supplies), Avantor's PS of 1.19x appears at a discount, suggesting the market is pricing in lower growth or higher risk. The EV/Sales multiple of 1.64x further supports a below-average valuation. Historical PS ratios are not available, but the current PS is likely near the lower end of its historical range given the stock's decline from $15.93 to $10.39. This low valuation could indicate a value opportunity if the company executes on its turnaround, but it also reflects the market's skepticism about near-term profitability.
PE
-14.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Avantor's negative net margin of -8.09% and operating margin of -3.76% indicate that the company is currently unprofitable, with a trailing EPS of -$0.068. The debt-to-equity ratio of 0.71 is manageable but adds fixed cost obligations that strain cash flow when earnings are negative. The high EV/EBITDA multiple of 81.84x implies that the market is pricing in substantial future profitability, leaving little room for error—any miss on earnings recovery could trigger a sharp de-rating. Additionally, the company's gross margin of 32.65% is vulnerable to rising petrochemical input costs, as highlighted by recent disruptions in the Strait of Hormuz, which could further delay the path to positive net income.
Market & Competitive Risks: Avantor's beta of 0.939 indicates slightly lower volatility than the market, but the stock's 1-year decline of -24.16% shows it has been highly sensitive to company-specific headwinds. The forward P/E of 12.21x, while low, is based on optimistic EPS estimates that may prove overly optimistic if biopharma demand softens or competition intensifies. The medical supplies industry is fragmented, and larger players with greater scale could pressure Avantor's pricing power. Regulatory risks in the healthcare sector, such as changes in FDA approval processes or reimbursement policies, could also impact demand for Avantor's products. The recent news about petrochemical cost increases from geopolitical tensions in the Strait of Hormuz is a tangible near-term risk that could compress margins before cost-saving initiatives take effect.
Worst-Case Scenario: In a severe downturn, Avantor could fail to achieve the expected earnings recovery due to persistent margin pressure from rising input costs and competitive pricing. If revenue growth stagnates and losses widen, the stock could fall to its 52-week low of $7.265, representing a potential loss of approximately -30% from the current price of $10.39. This scenario would likely involve multiple analyst downgrades and a loss of investor confidence, pushing the stock to levels not seen since early 2026. The historical max drawdown of -52.5% from the 52-week high of $15.93 to the low of $7.265 illustrates the magnitude of downside risk in adverse conditions.
FAQ
The primary risk is margin compression from rising petrochemical costs due to geopolitical tensions in the Strait of Hormuz, which could delay the return to profitability. Financially, the company has negative net margins of -8.09% and operating margins of -3.76%, meaning it is currently losing money. The high EV/EBITDA multiple of 81.84x leaves little room for error—any earnings miss could lead to a sharp de-rating. Additionally, the stock's 1-year decline of -24.16% reflects persistent bearish sentiment, and the short ratio of 4.26 days indicates elevated short interest, which could amplify downside if negative news hits. The most severe risk is a failure to achieve the estimated EPS of $1.04, potentially sending the stock back to the 52-week low of $7.265.
The 12-month outlook is cautiously optimistic, with a base case probability of 45% targeting a range of $10.39 to $12.70, aligned with the implied analyst target. The bull case (30% probability) sees the stock reaching $12.70 to $15.93 if the company returns to profitability and margins stabilize. The bear case (25% probability) projects a decline to $7.27-$9.00 if cost pressures persist and earnings miss estimates. The most likely scenario is the base case, where Avantor delivers on EPS estimates but faces modest headwinds, keeping the stock near current levels with gradual upside. Key assumptions include gross margins holding above 32% and revenue growth in line with the $7.37 billion estimate.
Avantor appears undervalued based on its price-to-sales ratio of 1.19x, which is well below the typical medical supplies industry range of 2-3x. The forward P/E of 12.21x is also reasonable for a company expected to return to profitability, and the PEG ratio of 0.08x suggests the stock is cheap relative to its estimated earnings growth. However, the trailing P/E is negative due to current losses, and the high EV/EBITDA multiple of 81.84x indicates the market is pricing in significant future earnings. Overall, the valuation is attractive if the company achieves the forecasted recovery, but the discount reflects the market's skepticism about near-term profitability.
Avantor presents a compelling risk/reward for investors willing to tolerate near-term uncertainty. The stock trades at a PS ratio of 1.19x, a discount to the medical supplies industry average of 2-3x, and analysts expect a sharp earnings recovery to $1.04 EPS, implying a forward P/E of 12.21x. The implied analyst target of ~$12.70 offers +22.2% upside from the current price of $10.39. However, the company is currently unprofitable with a net margin of -8.09%, and rising petrochemical costs from geopolitical disruptions pose a risk to margins. For value-oriented investors with a 12-month horizon, it could be a good buy if the earnings recovery materializes; for risk-averse investors, waiting for evidence of margin stabilization may be prudent.
Avantor is better suited for a medium-term investment horizon of 12-18 months, given the expected earnings recovery catalyst. The stock's beta of 0.939 indicates slightly lower volatility than the market, but the 1-year decline of -24.16% and high short ratio of 4.26 days suggest it is prone to sharp moves. For short-term traders, the recent 3-month momentum of +31.52% and short squeeze potential could offer opportunities, but the risk of margin headwinds makes it speculative. Long-term investors may find value if the company sustains profitability, but the lack of a dividend (yield 0%) and negative net margins make it less suitable for income-focused portfolios. A minimum holding period of 12 months is recommended to allow the earnings recovery to play out.